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ABSTRACT Transthyretin (TTR) amyloid fibril forma-
tion is observed systemically in familial amyloid polyneurop-
athy and senile systemic amyloidosis and appears to be the
causative agent in these diseases. Herein, we demonstrate
conclusively that thyroxine (10.8 mM) inhibits TTR fibril
formation efficiently in vitro and does so by stabilizing the
tetramer against dissociation and the subsequent conforma-
tional changes required for amyloid fibril formation. In
addition, the nonnative ligand 2,4,6-triiodophenol, which
binds to TTR with slightly increased affinity also inhibits TTR
fibril formation by this mechanism. Sedimentation velocity
experiments were employed to show that TTR undergoes
dissociation (linked to a conformational change) to form the
monomeric amyloidogenic intermediate, which self-assembles
into amyloid in the absence, but not in the presence of
thyroxine. These results demonstrate the feasibility of using
small molecules to stabilize the native fold of a potentially
amyloidogenic human protein, thus preventing the conforma-
tional changes, which appear to be the common link in several
human amyloid diseases. This strategy and the compounds
resulting from further development should prove useful for
critically evaluating the amyloid hypothesis—i.e., the putative
cause-and-effect relationship between TTR amyloid deposi-
tion and the onset of familial amyloid polyneuropathy and
senile systemic amyloidosis.
Transthyretin (TTR) is present in human plasma (0.2 mgyml;
3.63 mM, tetramer) and is composed of four identical b-sheet-
rich subunits that bind and transport thyroxine (T4) and the
retinol binding protein (1). In unfortunate individuals, TTR is
converted into an insoluble fibrillar structure called amyloid.
These fibrils putatively cause senile systemic amyloidosis
(wild-type TTR composes the fibrils-late onset) and familial
amyloid polyneuropathy (FAP; predominantly variant TTR
composing the fibrils-earlier onset) by virtue of the amyloid’s
neurotoxicity andyor by physically interfering with normal
organ function (2–8). A TTR amyloid fibril is '130Å in
diameter and made up of four protofilaments, each having a
twisted cross-b-helix structure (9, 10). TTR amyloid fibril
formation is observed during partial acid denaturation from a
conformational intermediate formed under conditions simu-
lating a lysosome (pH 5.56 0.5), which has been implicated in
fibril formation in vivo (11, 12). TTR amyloid fibril formation
can be avoided under acidic conditions by working at low TTR
concentrations and low temperature (258C) allowing identifi-
cation of the quaternary, tertiary, and secondary structure of
the intermediate(s) that can form amyloid (12). These studies
reveal that tetrameric TTR is nonamyloidogenic; however, the
dissociation of the tetramer into a monomeric intermediate
having an altered, but defined, tertiary structure is capable of
amyloid fibril formation and is therefore called the amyloido-
genic intermediate (Fig. 1). Several of the 50 FAP-associated
TTR single-site mutations still adopt a normal tetrameric
structure under physiological conditions (13–16); however,
these mutations significantly destabilize the tetramer (17, 18).
The mutation-induced destabilization allows the amyloido-
genic intermediate to be populated under lysosomal conditions
(pH 5.5) in the case of the FAP associated V-30-M (most
common FAP mutation) and the L-55-P TTR variants,
whereas the wild-type protein remains predominantly tet-
rameric and nonamyloidogenic.
The TTR tetramer has an hourglass-shaped central channel
where two molecules of T4 can bind at pH 7.4 (Ka values of 13
108 and 9.63 105 M21) (refs. 19 and 20; Fig. 2). However, only
10–25% of the TTR in plasma has T4 bound, because T4
binding globulin is the major T4 carrier in plasma (Ka of 6 3
109), binding'75%T4 present (22). Our strategy for inhibiting
TTR fibril formation systemically is to design a ligand that will
bind with high affinity to plasma TTR using the largely
unoccupied T4 binding site. Herein, we show that ligand
binding stabilizes TTR against amyloid formation, suggesting
a potential new therapeutic strategy for treating TTR amyloid
disease.
MATERIALS AND METHODS
Preparation of TTR, T4, and 2,4,6-Triiodophenol (TIP)
Solutions.Wild-type, L-55-P, and V-30-M TTR were purified
from an Escherichia coli expression system described previ-
ously (17). The extinction coefficient of wild-type TTR («2805
77,600) was used for V-30-M and L-55-P TTR, as reported
previously (17, 18). All studies reported in this paper use
recombinant TTR, because TTR isolated from aged plasma is
typically heterogeneous.
A concentrated stock solution of T4 (Calbiochem) was
prepared by dissolving T4 in 0.01 M NaOH and filtering the
solution through a 0.2-mm syringe filter. The T4 solution was
verified to be 99% pure by its single narrow peak in a reverse
phase HPLC trace, and its identity was established by matrix-
assisted laser desorption ionization (MALDI) mass spectrom-
etry (M15 778). The concentration of the solution was ob-
tained using its absorption at 325 nm («325 5 6185). Crude TIP
purchased from Aldrich was precipitated from ethanol three
times by the addition of H2O and purified by C-4 reverse phase
HPLC, and its structure was identified by GC-electron impact
MS (M1 5 472). The TIP was dried at 618C over P2O5 under
high vacuum and dissolved in 0.01 M NaOH to afford a 0.54
mM solution.
Amyloid Fibril Formation and Inhibition Thereof via Par-
tial Acid Denaturation. A series of 50 mM sodium acetate-
buffered 100 mM KCl solutions (1.2 ml) containing different
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amounts of T4 (or TIP) dissolved in 0.01 M NaOH were
prepared at the desired pH in Eppendorf tubes. Wild-type
TTR from a stock solution ('5 mg of TTR per ml in 10 mM
phosphate, pH 7.4y100 mM KCly1 mM EDTA) was then
added to each tube to obtain a final TTR concentration of 0.2
mgyml. In addition, two control samples containing TTR but
no inhibitor (T4 or TIP) and T4 or TIP but no TTR were also
similarly evaluated. Each stationary tube was incubated at
378C for 72 h to probe the viability of amyloid fibril formation
via partial TTR denaturation. The time course of TTR fibril
formation under these conditions has been reported previously
(see figure 2B in ref. 12) and demonstrates that amyloid fibril
formation plateaus after 72 h, justifying analysis of the inhib-
itors at 72 h. The extent of fibril formation was measured by
OD at 330 nm in a standard UV cell (23, 24) and by a
quantitative Congo red binding assay (12, 25) as described in
detail previously (12). Analogous studies were also carried out
with L-55-P and V-30-M TTR at pHs where these TTR
variants make amyloid (17, 18). The integrity of the amyloid
fibrils formed using the methods described above were con-
firmed by x-ray diffraction, as well as by light and electron
microscopy using methods described previously (11, 17) .
Probing Quaternary Structure Changes by Analytical Ul-
tracentrifugation.The effect of T4 on the quaternary structure
stability of wild-type TTR and single-site amyloidogenic vari-
ants thereof as a function of pH was evaluated using analytical
ultracentrifugation. The quaternary structural changes were
examined using sedimentation velocity and sedimentation
equilibrium techniques in the presence and absence of T4 using
a temperature-controlled Beckman XL-A analytical ultracen-
trifuge equipped with a An60Ti rotor and photoelectric scan-
ner. Double-sector aluminum cell centerpieces and quartz
windows were used in the velocity experiments at a tempera-
ture of 25 or 378C, using 400–420ml of sample and rotor speeds
of 3000–60,000 rpm. Sedimentation of wild-type TTR was
carried out at pH 4.4 (50 mM acetatey100 mM KCl). Con-
centrated TTR stock solutions were spun down on a desktop
centrifuge for 15 min at 48C, and all buffers were filtered
through 0.2-micron filter before use. TTR samples (0.2 mgyml)
in the presence or absence of 10.8 mM T4 were prepared as
described in the amyloid fibril formation section. After an
incubation period of 48 h at 258C or 72 h at 378C, the samples
were loaded into a double-sector cell and evaluated at 235 nm.
TTR samples lacking T4 incubated at 378C were not evaluated
in the centrifuge due to extensive amyloid fibril formation. For
boundary sedimentation analysis, the movement of the mid-
point (r) of the absorbance boundary vs. time (t) was used to
obtain the uncorrected sedimentation coefficient s*, expressed
in Svedberg units, from the slope of the plot of lnr vs. tyv2 (i.e.,
dlnryv2dt). The observed s* values obtained were corrected to
standard conditions by Eq. 1 using tabulated density and
viscosity data (26):







where r and h are the density and viscosity of the solvent at the
temperature of the sedimentation velocity experiment or the
viscosity of water at 208C, and y# is the partial specific volume
of the protein under the conditions of the experiment. The
sedimentation coefficients s20,w for the TTR tetramer (4.2 6
0.2 S) was determined by sedimentation velocity experiments
at pH 7, where the tetramer is the dominant species based on
sedimentation equilibrium measurements.
Sedimentation equilibrium runs were performed on 130-ml
samples from 3000–15,000 rpm using double-sector cells with
charcoal-filled Epon centerpieces and sapphire windows. All
scans were performed at 280 nm with a step size of 0.001 and
30–50 averages. Samples were allowed to equilibrate over
18–24 h, and duplicate scans 3 h apart were overlaid to
determine that equilibrium had been reached. The data were
analyzed by a nonlinear least square analysis (27) using the
ORIGIN software provided by Beckman (y# 5 0.7347 based on
amino acid composition). The data were fit to a single ideal
species model using Eq. 2 to determine the best-fitting mo-
lecular weight.
Ar 5 Exp@ln~A0! 1 ~Mv2~1 2 yr!y2RT! z ~x2 2 x02!# 1 E, [2]
where Ar is the absorbance at radius x; Ao is the absorbance at
a reference radius xo, usually the meniscus; y# is the partial
specific volume of TTR (mlymg); r is the density of the solvent
(mgyml); v is the angular velocity of the rotor (radianysec); E
is the baseline error correction term; M is the gram molecular
weight; R is the universal gas constant 8.314 3 107 ergymolzK
(1 erg 5 0.1 mJ); and T is temperature (in K).
FIG. 1. Schematic representation of the acid-mediated denatur-
ationyamyloid fibril-forming pathway of TTR.
FIG. 2. Ribbon diagram of tetrameric TTR illustrating the hour-
glass-shaped channel that runs through the center of the protein and
serves as the binding site for T4 (3,39-diiodothyroxine shown) mole-
cules rendered as a space-filling structure (21). The four conserved
water molecules are also shown in CPK (Corey–Pauling Space Filling
Models) format.
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Equilibrium Dialysis Evaluation of the Binding of T4 to
TTR. Equilibrium dialysis was used to evaluate the binding
stoichiometry of T4 to TTR under acidic conditions with
protein and ligand concentrations identical to the concentra-
tions used in the amyloid fibril formation and inhibition assay.
The top chamber of the FT4-Nelson Dialysis Cell (Nichols
Institute, San Juan Capistrano, CA), was filled with 2.5 ml of
50 mM acetate buffer containing 0.2 mg of (3.63 mM, tet-
ramer) recombinant wild-type TTR per ml and a known
amount of cold T4 with a trace amount of purified I125-labeled
T4. The bottom chamber was filled with 2.5 ml of acetate
buffer only. After 5 days of incubation at 258C, 200-ml aliquots
from each chamber were analyzed in a UKB–Wallac (Gaith-
ersburg, MD) Ria Gamma 1274 Counter to determine the
fraction of T4 bound. The number of moles T4 bound to TTR
was determined by multiplying the fraction of T4 bound by the
total T4 concentration divided by the TTR concentration. A
Scatchard analysis to determine the binding constant of T4
(1.53 1026–33 1026 M) to TTR (0.05 mgyml) at pH 4.4 could
only be estimated, owing to the complications resulting from
TTR dissociation at T4 concentrations lower than 1.5 3
1026M. A Scatchard analysis of the binding of T4 (1 3
1028–3 3 1026 M) to TTR at pH 7.4 (0.05 mgyml) was
straightforward (20, 28).
RESULTS
The efficacy of T4 as an inhibitor of wild-type TTR fibril
formation was demonstrated by incubating varying concentra-
tions of T4 with TTR under acidic conditions, previously
shown to effect fibril formation in vitro (11, 12). TTR fibril
formation is maximal at pH 4.4 and is nearly completely
inhibited by the addition of 3 eq of T4 (10.8 mM). Fibril
formation was evaluated by OD measurements and by quan-
titative Congo red binding studies over a 72-h period (Fig. 3A),
sufficient for TTR fibril formation to reach a maximum and
plateau in the absence of inhibitor (12). As expected, the extent
of fibril inhibition decreases with a decrease in added T4 (Fig.
3A). The inhibitory effect of T4 reaches amaximum at 10.8mM
(3 eq), where T4 binding occurs at both the low and high
affinity sites in the TTR tetramer (0.2 mgyml) as demonstrated
by the binding studies (29). To be certain the inhibitory nature
of T4 is not pH-specific, we evaluated TTR fibril growth
inhibition at 10.8 mM T4 over the pH range of 4.2–5.0, where
wild-type TTR is amyloidogenic. The inhibitory effect ob-
served at pH 4.2 and 4.6 was nearly identical to that observed
at pH 4.4 (data not shown). The effectiveness of T4 as a fibril
inhibitor at pH 4.8 and 5 was not easy to evaluate, as only traces
of wild-type fibrils are formed under these conditions in the
absence of inhibitor (12). To be certain that T4 serves as an
inhibitor of TTR fibril formation around pH 5, the L-55-P and
V-30-M FAP single-site variants of TTR were studied in the
absence and presence of T4. We have previously demonstrated
that these amyloidogenic variants are much less stable than the
wild-type protein and form the monomeric amyloidogenic
intermediate, which self-assembles into amyloid at pH around
5, where the wild-type protein is largely tetrameric and resis-
tant to fibril formation (17, 18). Fibril formation normally
exhibited by the V-30-M and L-55-P TTR around pH 5 is
efficiently inhibited by the addition of 10.8mMT4 (Fig. 3 B and
C). The extent of inhibition is proportional to the amount of
T4 added up to 10.8 mM, at which concentration both binding
sites on TTR are saturated (Fig. 3A). Interestingly, the other
natural ligand for TTR, the retinol binding protein, does not
inhibit TTR fibril formation, because retinol binding protein
does not bind TTR under fibril-forming conditions (G.J.M.
and J.W.K., unpublished results).
Biophysical studies carried out in this laboratory have shown
that tetrameric TTR (having a sedimentation coefficient s20,w
5 4.2 6 0.2 S, expressed in Svedberg units) must dissociate to
FIG. 3. Inhibition of TTR amyloid fibril formation by T4 and
TIP. The extent of fibril formation in the presence and absence of
inhibitor at pH 4.4 was probed at 72 h by an optical density
measurement at 330 nm (hatched bars) and by a quantitative Congo
red binding assay (solid bars). (A) Wild-type fibril formation. From
left to right, fibril formation in the absence of T4 and in the presence
of T4 alone (no TTR) and TTR fibril formation in the presence of
the indicated equivalents of T4 (3 eq of T4 5 10.8 mM) are shown.
Inhibition of (B) V-30-M and (C) L-55-P TTR by T4 at pH 5.0. (D)
Inhibition of wild-type TTR by TIP. The labeling of the axes and the
organization of the data in B–D is the same as that in A.
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monomer (s20,w 5 1.6 6 0.2 S) and undergo a conformational
change to self-assemble into amyloid (11, 12, 17, 18, 30). In the
absence of T4, TTR exists as a mixture of quaternary species
at pH 4.4 (258C), including the monomeric amyloidogenic
intermediate as discerned from the velocity profile of wild-type
TTR (Fig. 4A). Analysis of the two separate boundaries using
the second moment method gave an average s value of 4.8 S
for the fast-moving species and 1.75 S for the slow-moving
boundary. Since this simple analysis cannot determine the
number of components in each boundary, the ‘‘dcdt’’ method
for calculating the apparent sedimentation coefficient distri-
bution, g*(s)t, for sedimenting samples was used (31). This
analysis identifies multiple sedimenting species with s25 values
of (1.5 S, 4.3 S, 5.4 S, and 6.3 S; Fig. 4B), corresponding to the
amyloidogenic monomeric intermediate, the acid-rearranged
tetramer, and two higher-order aggregated species, respec-
tively. The higher-order assemblies may be on the pathway to
amyloid but have not yet been identified. Wild-type TTR and,
to a greater extent, V-30-M and L-55-P TTR exhibit significant
aggregation in the absence of T4, indicating their instability
toward acid denaturation and subsequent self-assembly, com-
plicating the sedimentation analysis.
In the presence of 10.8 mM T4, wild-type TTR exclusively
sediments as a single symmetrical band at pH 4.4 with an s
value close to that of the tetramer under physiological condi-
tions (Fig. 5A). The V-30-M and L-55-P TTR variants with
bound T4 also show the movement of a single boundary across
the cell with identical s values (4.8 S) at 258C corresponding to
tetrameric TTR. The second moment analysis of the sedimen-
tation data in the presence of 10.8 mM T4 gave the following
s values at 258C, 378C, and corrected to 208C in water for
wild-type, V-30-M, and L-55-P TTR, respectively: s25,buffer 5
4.9 S, 4.8 S, and 4.8 S; s37,buffer 5 5.8 S, 5.9 S, and 6.2S; s20,w 5
4.2 6 0.2 S, 4.1 6 0.1 S, and 4.3 6 0.2 S, demonstrating the
presence of tetrameric TTR at pH 4.4.
From sedimentation equilibrium analysis of wild-type TTR
at pH 4.4 (0.2 mgyml) in the presence of T4 (10.8 mM), no
heterogeneity could be detected upon linearization of the
sedimentation equilibria. The fit of the exponential to a single
species gave an average molecular weight of 52,720 gymol,
which corresponds to the molecular weight of the tetramer
(54,980 from amino acid composition; Fig. 5B). These data,
along with the binding data presented below, demonstrate that
2 mol of T4 bind to and stabilize the normal quaternary
structure of TTR, thus preventing denaturation-mediated
FIG. 4. (A) Sedimentation velocity profile of wild-type TTR in the
absence of T4 at pH 4.4. Solute distribution recorded at 235 nm (60,000
rpm). Scans for analysis were recorded every 3 min; for simplicity, only
scans from every 24 min are shown. (B) Apparent sedimentation
coefficient distribution (g*(s)t) as a function of sedimentation coeffi-
cient for wild-type TTR (0.2 mgyml) in the absence of T4, indicating
the formation of multiple species during the partial acid denaturation
of TTR.
FIG. 5. (A) Sedimentation velocity profile of wild-type TTR in the
presence of T4 at pH 4.4. Solute distribution recorded at 235 nm
(60,000 rpm). Scans for analysis were recorded every 3 min; for
simplicity, only scans from every 15 min are shown. (B) Sedimentation
equilibrium analysis of wild-type TTR at pH 4.4 in the presence of 10.8
mM. The solid line drawn through the data was obtained by fitting the
absorbance vs. radial position r to Eq. 2 for a homogeneous tetrameric
species. The residual difference between the experimental data and
the fitted data for each point is shown in the Inset.
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fibril formation. Attempts to carry out equilibrium ultracen-
trifugation experiments on V-30-M and L-55-P in the presence
of T4 failed due to their instability in the centrifuge for long
periods of time.
T4 binding to wild-type TTR was evaluated at pH 4.4 to be
sure that the binding constant for T4 did not change signifi-
cantly at lower pH. At physiological TTR concentration (0.2
mgyml), it is clear that two equivalents of T4 are bound to TTR
at 10.8 mM T4, which is also the case for T4 binding to TTR
at pH 7.4. A Scatchard analysis cannot be rigorously accom-
plished at pH 4.4 because of TTR dissociation (0.05 mgyml) or
dissociation and amyloid formation (0.2 mgyml) at low T4
concentrations, which complicates the evaluation of the bind-
ing curves. A fit of a portion of the T4 binding data to TTR at
pH 4.4 over the T4 concentration range (1.5–3 3 1026 M),
where TTR is largely tetrameric yields an apparent binding
constant of 6.43 105 M21 for binding to both the low and high
affinity sites. A Scatchard analysis of the binding of T4 to TTR
at pH 7.4 yields the expected values (Ka1 5 2.3 3 107 6 6 3
106 M21; Ka2 5 4.8 3 105 6 2 3 105 M21), corroborating the
authenticity of the recombinant protein and the validity of the
methods used at pH 4.4.
To verify the generality of this small molecule approach to
inhibit TTR fibril formation, we studied the commercially
available nonnatural ligand TIP, which is reported to bind TTR
with 3-fold higher affinity relative to T4 (32). This simple
phenol also efficiently inhibits TTR fibril formation and
appears to be very similar to T4 in terms of its efficacy (Fig.
3D). These results have motivated our lab to design and
synthesize high affinity small molecule inhibitors of TTR fibril
formation using a structure-based design approach.
DISCUSSION
The deposition of a normally soluble protein into cross-b amyloid
fibrils is the hallmark of human amyloid disease (6, 33, 34). There
is ample evidence to show that conformational changes are
sufficient for the conversion of a number of normally soluble
human proteins into amyloid fibrils, including the immunoglob-
ulin light chains, lysozyme, and TTR, and variants thereof (11, 12,
34–36). Fibril formation is believed to be intimately involved in
the pathological mechanism of human amyloid disease based on
the demonstrated neurotoxicity of amyloid fibrils produced in
vitro, the observation of lower levels of amyloid in age-matched
controls relative to Alzheimer disease patients, and the correla-
tion of improved health with the clearance of amyloid in FAP
patients, where liver transplantation is used to replace mutant
TTR with wild-type TTR (37). The amyloid hypothesis has been
difficult to prove, and, as a result, the pharmaceutical industry has
been reluctant to make a large commitment in the amyloid
disease area until the pathogenic mechanism becomes more
clearly established (6, 34).
At the present time, there is no general strategy for treating
human amyloid disease. The results presented within are
important because the strategy of using ligand binding to
stabilize the native protein conformation may prove useful for
other monomeric and oligomeric amyloidogenic proteins,
which adopt well-defined physiological conformations. More-
over, medicinal chemists are very good at making high affinity
ligands for proteins and at understanding structure–activity
relationships using the principles of structure-based drug
design (38, 39). Last, and perhaps most importantly, the
approach demonstrated within produces molecules that may
allow scientists to probe the pathogenic mechanisms of certain
amyloid diseases in animal models and ultimately in humans
(40). With molecules that inhibit TTR amyloid formation, one
could ask and answer a very important question: Does the
inhibition of amyloid fibril formation inhibit the onset of
amyloid disease?
The results presented within demonstrate that T4 and TIP
are effective inhibitors of TTR amyloid fibril formation in vitro
at an inhibitor concentration of 10 mM. It is important to point
out that the physiological concentration of TTR is 0.2 mgyml
(3.63 mM, tetramer), and, therefore, even if the binding
constant of the inhibitor were 1010 M21, the mechanism of
inhibition still requires a 7.26 mM inhibitor concentration in
plasma to occupy both sites in TTR. The sedimentation
velocity experiments of wild-type TTR and variants thereof
showed that in the absence of T4 at acidic pH values, TTR
forms amyloid and exists in multiple quaternary forms in
solution, including the monomeric amyloidogenic intermedi-
ate. However, in the presence of three equivalents of T4,
wild-type and variant TTR are stabilized in a tetrameric
nonamyloid form at acidic pH values, as discerned by sedi-
mentation velocity and equilibrium ultracentrifuge data. How-
ever, T4 does not prevent fibril formation systemically in
humans by binding to TTR, because the majority of T4
(.75%) is bound to T4 binding globulin, which has a higher
affinity (6 3 109 M21) for T4 than TTR. Contrary to the case
in plasma, TTR is the major T4 carrier in the cerebral spinal
f luid, perhaps explaining why TTR fibril formation is generally
not observed in the brain [ref. 41; occasionally TTR fibrils are
observed in the blood vessels of the choroid plexus, which is the
site of TTR synthesis in the cerebrospinal f luid (42)]. Based on
the in vitro results presented, a synthetic T4 mimic that is
neither an agonist nor antagonist (does not bind to the thyroid
receptor) and that has higher affinity for TTR than T4 binding
globulin may prove to be an effective TTR amyloid fibril
inhibitor systemically in vivo. This strategy should prove to be
general for inhibiting fibril formation in the case of the
wild-type TTR, which putatively causes senile systemic amy-
loidosis, and for the vast majority of the TTR variants asso-
ciated with FAP, since in the majority of the cases the T4
binding is unaffected. There are a few reported mutations out
of the 50 examples of FAP-associated TTR variants that
appear to be incapable of T4 binding due to altered T4 binding
sites, implying that these particular cases may not be suscep-
tible to small molecule inhibition (43). However, it may be
possible based on structure–activity relationships to design a
molecule that will bind to all 50 FAP variants with higher
affinity than TIP, but that remains to be seen. Recent dem-
onstrations that amyloid can be cleared in vivo suggest that
there may be a delicate balance between fibril formation and
fibril clearance (44). Even if a given compound were only
moderately effective as an inhibitor of TTR fibril formation,
it still may prove effective as a therapeutic agent, because it
may only be necessary to slightly shift the balance between
synthesis and degradation of amyloid to avoid the onset of
amyloid disease (34). All indications are that humans can
tolerate low levels of amyloid deposition, but not high levels.
The strategy outlined here where a ligand is used to stabilize
the normal structure of a protein against deleterious confor-
mational changes should prove useful for preventing fibril
formation in other amyloid diseases where the precursor
protein is structurally well-defined and undergoes denatur-
ation before self-assembly into amyloid but may not easily be
applied in Alzheimer disease, where the b-peptide exhibits
conformational heterogeneity in normal individuals.
CONCLUSION
A common mechanistic hypothesis appears to be operating in
several, but perhaps not all amyloid diseases, where a normally
folded protein undergoing a conformational change yields an
amyloidogenic intermediate that self-assembles into amyloid
fibrils (34). We demonstrate a potentially useful therapeutic
strategy for TTR-based amyloid diseases where the amyloi-
dogenic protein of interest is stabilized against partial dena-
turation by ligand binding to the native state, making the
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conformational change affording the amyloidogenic interme-
diate difficult to achieve, thus preventing fibril formation.
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